Adial Pharma Says Purnovate's PNV-6005 Reports Positive Data In Treating Ulcerative Colitis
(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL) announced Tuesday that Purnovate, Inc., a subsidiary of Adial, achieved positive in-vivo data from its study with mice treated with Purnovate's PNV-6005 as a potential treatment for inflammatory bowel diseases.
PNV-6005 is a selective adenosine 2A receptor agonist designed to have anti-inflammatory properties and protective effects against colitis and other inflammatory bowel diseases (IBD).
In the study, PNV-6005 demonstrated statistically significant effect against both primary study endpoints, which are pre-clinical endpoints expected to indicate potential efficacy against ulcerative colitis in humans.
Specially, PNV-6005 significantly prevented weight loss as compared to the control group (greater than 50% inhibition of weight loss). It also significantly prevented colon damage as evidenced by reduction of shortening of colon lengths in the PNV-6005 treated group (almost total prevention), as well as a decrease in inflammation as assessed histologically.
Adial Pharmaceuticals Names Director Tony Goodman As Chief Operating Officer
Powell Warns There's 'No Risk-Free Path' For Interest Rates
Hungary Holds Rates Steady As Inflation Expected To Remain High
Bay Street Likely To Post New Highs
Wall Street Likely To Open Flat
Sweden Cuts Policy Rate By 25 Bps
FTSE 100 Flat; Kingfisher Soars On Higher Guidance
